id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353749-2vlc11rx	Stricker, Raphael B	Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19	2020-10-19		.txt	text/plain	3090	200	50	24 In one uncontrolled study, HCQ prophylaxis in a hospital setting with a known SARS-CoV-2 exposure prevented dissemination of viral infection. 40 The second case-control study of HCWs found that four or more weekly doses of HCQ resulted in significantly less infection with SARS-CoV-2 (adjusted odds ratio 0.44, p<0.001). 45 In a retrospective cohort study of 32,109 rheumatic disease patients from the US Veterans Health Administration, the incidence of SARS-CoV-2 infection was equivalent regardless of chronic HCQ use (0.3% in users versus 0.4% in non-users), but mortality was significantly decreased in patients taking HCQ (odds ratio 0.70, p=0.0031). SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: implications for prophylaxis Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection	./cache/cord-353749-2vlc11rx.txt	./txt/cord-353749-2vlc11rx.txt